Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Zymeworks in a research note issued to investors on ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) announced the US Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi ...

Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...

An in-depth analysis of recent analyst actions unveils how financial experts perceive CVS Health. The following summary ...

Democratic lawmakers warn President Trump of severe health and financial impacts if HIV prevention funding is cut. Read more here.

Citizens JMP downgraded Elevation Oncology (ELEV) to Market Perform from Outperform with no price target after the company announced the ...

We will begin the MacroGenics fourth quarter and full-year 2024 corporate progress and financial results conference call in just a moment. All participants are in a listen-only mode. And we will ...